Hostname: page-component-7c8c6479df-5xszh Total loading time: 0 Render date: 2024-03-28T19:24:25.472Z Has data issue: false hasContentIssue false

The need for close monitoring of early psychosis and co-occurring substance misuse

Published online by Cambridge University Press:  02 January 2018

Carol L. M. Caton*
Affiliation:
Columbia University, New York, USA
*
Carol L. M. Caton (clc3@columbia.edu)
Rights & Permissions [Opens in a new window]

Summary

Substance misuse is widespread among individuals with early-phase psychotic disorders and is associated with a worse illness course. Thorough assessment of patterns of substance misuse at admission for psychiatric care is often lacking and can compromise the accuracy of a diagnostic assessment that distinguishes between a primary psychosis and one that is substance induced. Given the risk to recovery from psychosis posed by substance misuse, close monitoring of the course and treatment of early-phase psychosis that is accompanied by substance misuse is indicated and could inform the development of more effective dual-diagnosis treatments.

Type
Editorial
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 2011

When individuals with recent-onset psychotic symptoms present for treatment, the clinical picture often includes substance misuse. Widespread among those with psychotic disorders, Reference Phillips and Johnson1,Reference Weaver, Madden, Charles, Stimson, Renton and Tyrer2 lifetime substance use disorder among individuals presenting with a first episode of psychosis has been observed in about a third to a half of those admitted for treatment, Reference Van Mastrigt, Addington and Addington3-Reference Wade, Harrigan, Edwards, Burgess, Whelan and McGorry7 a rate that is significantly higher than that found in the general population. Reference Kessler, Berglund, Demler, Jin, Merikangas and Walters8,Reference Volkov9 It has been well documented that comorbid substance misuse compromises recovery in psychosis and is associated with a host of negative outcomes, Reference Caton, Samet and Hasin10 including increased risk of relapse of positive symptoms, Reference Foti, Kotov, Guey and Bromet11 in-patient readmission, Reference Wade, Harrigan, Edwards, Burgess, Whelan and McGorry7 non-adherence to treatment, Reference Addington and Addington12 and poorer functional outcome. Reference Turkington, Mulholland, Rushe, Anderson, McCaul and Barrett13 If this dim outlook is not enough to warrant close scrutiny of this patient group, recent studies have identified issues that underscore the importance of evaluating patterns of substance use and misuse and monitoring the relationship of substance use to psychiatric symptomatology.

The association of substance misuse and psychosis

The most common substances of misuse such as alcohol, Reference Schuckit14 cocaine, Reference Satel and Edell15 amphetamine, Reference McLellan, Woody and O'Brien16,Reference Angrist, Cho and Segal17 hallucinogens Reference Bowers and Swigar18 and cannabis Reference D'Souza, Perry, MacDougall, Ammerman, Cooper and Wu19 have psychotomimetic properties that can produce psychotic reactions in individuals who are otherwise free of severe mental illness. Use of these drugs by individuals with primary psychotic disorders, such as schizophrenia and bipolar disorder, often results in presenting symptoms that are similar to those seen in individuals showing psychotic reactions due to drugs alone.

Cannabis ranks high among the world’s popular recreational drugs and is the most extensively used illicit substance by people with psychotic disorders. Reference Koskinen, Lohonen, Koponen, Isohanni and Miettunen20 Tetrahydrocannabinol (THC) is an active psychopharmacological ingredient in cannabis which, when used to intoxication, can lead to acute and transient psychotic symptoms in some people and recurrences of psychotic symptoms among certain individuals with known psychotic disorders. Reference Minozzi, Davoli, Bargagli, Amato, Vecchi and Perucci21 Cannabis is also the most comprehensively researched drug in relation to psychosis. Systematic reviews of cannabis and psychosis repeatedly confirm an association between exposure to cannabis and psychosis. Reference Minozzi, Davoli, Bargagli, Amato, Vecchi and Perucci21-Reference Moore, Zammit, Lingford-Hughes, Barnes, Jones and Burke25 Although it has been suggested that cannabis may play a role in the aetiology of psychosis, the contention that cannabis use can cause a long-term psychosis remains controversial.

The rapidly developing work in this field has, however, yielded findings that can guide clinicians in their treatment of individuals with early symptoms of psychosis. Early cannabis use and a longer duration of use have been found to be associated with psychosis-related outcomes in young adults, Reference McGrath, Welham, Scott, Varghese, Degenhardt and Hayatbakhsh26 whereas lifetime cannabis use has been found to be associated with an earlier onset of psychosis. Reference Foti, Kotov, Guey and Bromet11 Importantly, it has been revealed that patients with first-episode psychosis were more likely to use high-potency cannabis (sensemilla, ‘skunk’) for longer periods and with greater frequency compared with a non-patient control group. Reference Di Forti, Morgan, Dazzan, Pariante, Mondelli and Marques27 High-potency cannabis is growing in popularity in some parts of Europe, and its use among people admitted for psychiatric treatment should be assessed. It is important to keep in mind, however, that availability and trends in use of alcohol and illicit substances vary considerably by region. More information on the relationship of other substances of misuse, including polydrug use, to the onset and course of psychotic disorders is needed.

Documenting patterns of substance use and misuse

Underdetection of comorbid substance use at admission for psychiatric care has been reported. Ley et al Reference Ley, Jeffery, Ruiz, McLaren and Gillespie28 compared the results of urinalysis with information on drug use taken from patient records, and found that of cases positively identified through urinalysis, 54% were not identified in case notes. This study underscores the need for a thorough drug use history that elicits information on age at first drug use (specific to drug of use, including alcohol), type and amount of drugs used, including high-potency cannabis and use of drugs in combination, route of administration (oral, smoked, injected), and whether drug use was either prompted or followed by any psychiatric symptom, including psychosis. Urine toxicology screens at treatment admission, obtained with consent, and efforts to obtain collateral reports on drug use from family members and significant others can complement patient self-reports. Patterns of lifetime use should be distinguished from use in the immediate period preceding admission, to determine whether drug use might be related to the onset of psychosis. Finally, an assessment of whether the person meets diagnostic criteria for misuse or dependence should be determined, as this signals a need for substance misuse treatment.

Determining the diagnostic distinction between primary and substance-induced psychotic disorders

Primary psychotic disorders and substance-induced psychotic disorders are distinct diagnostic entities with fundamentally different treatment needs. Reference Caton, Hasin, Shrout, Drake, Dominguez and First29 A diagnostic assessment that thoroughly differentiates these disorders is particularly important in the early stages of psychotic disorder, when an appropriate match of diagnosis and treatment has critical implications for outcome. However, in the initial stages of a first psychotic episode diagnostic certainty can be elusive. Under all circumstances, minimising the risk of harm to self or others and prompt treatment of psychotic symptoms are warranted. Although there remains a lack of information on the course and outcome for the management of substance-induced psychosis, Reference Mathias, Lubman and Hides30 current diagnostic criteria specify that remission of psychotic symptoms following acute intoxication and withdrawal suggests that the psychosis is substance induced. If psychotic symptoms persist during a period of drug abstinence in excess of 4 weeks, it is likely that the psychosis is not related to withdrawal and is therefore primary. 31,32

A common denominator in both conditions is the presence of psychotic symptoms, which often fluctuate in the early stages of illness. Given the mounting evidence that a longer duration of untreated psychosis is associated with a worse clinical outcome, Reference Marshall, Lewis, Lockwood, Drake, Jones and Croudace33 treatment of psychotic symptoms should not be delayed, regardless of psychosis diagnosis or the extent of substance misuse. In all circumstances, frequent follow-up visits, including outreach, are warranted to confirm diagnostic accuracy Reference Caton, Samet and Hasin10 and treatment efficacy.

Thorough follow-up of individuals with an initial diagnosis of substance-induced psychosis is particularly important, Reference Crebbin, Mitford, Paxton and Turkington34 since findings suggest that those with poorer premorbid functioning, less insight into psychosis, and greater prevalence of family mental illness are at risk of being re-diagnosed with primary psychotic disorder in a future episode. Reference Caton, Hasin, Shrout, Drake, Dominguez and First29 Treatment guidelines for the management of early-phase substance-induced psychosis, including the optimal duration of antipsychotic treatment, are not well established compared with those for primary psychotic disorder. Reference Dawson, Green, Drake, Lavori, McGlashan and Schanzer35 Even so, minimal treatment recommendations would address the substance use problem and the need to monitor persistent or recurrent psychotic symptoms. Reference Drake, Caton, Xie, Hsu, Gorroochurn and Samet36 Just as there are risks to the inadequate detection and treatment of psychotic symptoms in the early phase of primary psychotic disorders, there are also risks to the underdetection of substance-induced psychotic disorders. Schanzer et al Reference Schanzer, First, Dominguez, Hasin and Caton37 compared emergency department diagnoses with research diagnoses made by psychiatrists and found that patients given an emergency department diagnosis of primary psychosis but found by the research diagnosis to have substance-induced psychosis were significantly more likely to be treated for a primary psychotic disorder rather than for substance-induced psychosis. An incorrect diagnosis of primary psychotic disorder when the symptoms are substance induced is of particular concern because of the long-term consequences, which can include unnecessary hospital admissions, inappropriate treatment with antipsychotic medication with their potential for serious side-effects, and failure to receive appropriate treatment for substance misuse.

Implications for care

Recognition of the extent of comorbid substance misuse among individuals with psychotic disorders has stimulated research that expands our understanding of the effect of substance misuse on psychosis, its course and outcome. Evidence to date suggests the wisdom of informing young adults seeking psychiatric treatment and members of their families about the risks that substance misuse, including cannabis use, may pose to their future mental health and well-being. Reference Moore, Zammit, Lingford-Hughes, Barnes, Jones and Burke25,Reference Hall and Degenhardt38 Further, interventions such as motivational interviewing, Reference Miller and Rollnick39 cognitive-behavioural therapy 40 and assertive outreach Reference Burns and Firn41 may prove useful in engaging poorly motivated individuals misusing substances who are in need of substance-misuse treatment. Reference Crebbin, Mitford, Paxton and Turkington34 A thorough assessment of patterns of substance misuse and close monitoring of the course and treatment of early-phase psychosis that is accompanied by substance misuse is indicated and could inform the development of more effective dual-diagnosis treatments for this complex comorbidity. Reference Tyrer and Weaver42,Reference Johnson, Thornicroft, Afuwape, Leese, White and Hughes43

Footnotes

Declaration of interest

None.

References

1 Phillips, P, Johnson, S. Drug and alcohol misuse among in-patients with psychotic illnesses in three inner-London psychiatric units. Psychiatr Bull 2003; 27: 217–20.Google Scholar
2 Weaver, T, Madden, P, Charles, V, Stimson, G, Renton, A, Tyrer, P, et al. Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. Br J Psychiatry 2003; 183: 304–13.Google Scholar
3 Van Mastrigt, S, Addington, J, Addington, D. Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol 2004; 39: 6972.Google Scholar
4 Barnes, TRE, Mutsatsa, SH, Hutton, SB, Watt, HC, Joyce, EM. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 2006; 188: 237–42.CrossRefGoogle ScholarPubMed
5 Mauri, MC, Vovonteri, LS, DeGaspari, IF. Substance abuse in first episode schizophrenic patients: a retrospective study. Clin Pract Epidemiol Ment Health 2006; 2: 411.Google Scholar
6 Barnett, JH, Werners, U, Secher, SM, Hill, KE, Brazil, R, Masson, K, et al. Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 2007; 190: 515–20.Google Scholar
7 Wade, D, Harrigan, S, Edwards, J, Burgess, PM, Whelan, G, McGorry, PD. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry 2006; 189: 229–43.CrossRefGoogle ScholarPubMed
8 Kessler, RC, Berglund, P, Demler, O, Jin, R, Merikangas, KR, Walters, EE. Lifetime prevalence and age-of-onset of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593602.Google Scholar
9 Volkov, ND. Substance use disorders in schizophrenia – clinical implications of comorbidity. Schizophr Bull 2009; 35: 469–72.Google Scholar
10 Caton, CLM, Samet, S, Hasin, DH. When acute-stage psychosis and substance use co-occur: differentiating substance-induced and primary psychotic disorders. J Psychiatr Pract 2000; 6: 256–66.Google Scholar
11 Foti, DJ, Kotov, R, Guey, LT, Bromet, EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry 2010; 167: 987–93.CrossRefGoogle ScholarPubMed
12 Addington, J, Addington, D. Effect of substance misuse in early psychosis. Br J Psychiatry 1998; 172 (suppl 33): s1346.Google Scholar
13 Turkington, A, Mulholland, CC, Rushe, TM, Anderson, R, McCaul, R, Barrett, SL, et al. Impact of persistent substance misuse on 1-year outcome in first-episode psychosis. Br J Psychiatry 2009; 195: 242–8.Google Scholar
14 Schuckit, MA. Drug and Alcohol Abuse, 3rd edn. Plenum Publishing, 1989.CrossRefGoogle Scholar
15 Satel, SL, Edell, WS. Cocaine-induced paranoia and psychosis proneness. Am J Psychiatry 1991; 148: 1708–11.Google Scholar
16 McLellan, AT, Woody, GE, O'Brien, CP. Development of psychiatric illness in drug abusers: possible role of drug preference. N Engl J Med 1979; 301: 1310–4.CrossRefGoogle Scholar
17 Angrist, B. Amphetamine psychosis: clinical variations of a syndrome. In Amphetamine and its Analogs (eds Cho, AK, Segal, DS): 387414. Academic Press, 1994.Google Scholar
18 Bowers, MB, Swigar, ME. Vulnerability to psychosis associated with hallucinogen use. Psychiatry Res 1983; 9: 91–7.Google Scholar
19 D'Souza, DC, Perry, E, MacDougall, L, Ammerman, Y, Cooper, T, Wu, YT, et al. The psychotomimetic effect of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacol 2004; 29: 1558–72.CrossRefGoogle ScholarPubMed
20 Koskinen, J, Lohonen, J, Koponen, H, Isohanni, M, Miettunen, J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 2010; 36: 1115–30.Google Scholar
21 Minozzi, S, Davoli, M, Bargagli, AM, Amato, L, Vecchi, S, Perucci, CA. An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results. Drug Alcohol Rev 2010; 29: 304–17.CrossRefGoogle ScholarPubMed
22 Arseneault, L, Cannon, M, Witton, J, Murray, RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184: 110–7.Google Scholar
23 Semple, DM, McIntosh, AM, Lawrie, SM. Cannabis as a risk factor for psychosis; systematic review. J Psychopharmacol 2005; 19: 187–94.Google Scholar
24 Henquet, C, Murry, R, Linszen, D, van Os, J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull 2005; 31: 608–12.Google Scholar
25 Moore, TH, Zammit, S, Lingford-Hughes, A, Barnes, TR, Jones, PB, Burke, M, et al. Cannabis use and the risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319–28.Google Scholar
26 McGrath, J, Welham, J, Scott, J, Varghese, D, Degenhardt, L, Hayatbakhsh, MR, et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry 2010; 67: 440–7.Google Scholar
27 Di Forti, M, Morgan, C, Dazzan, P, Pariante, C, Mondelli, V, Marques, TR, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009; 195: 448–91.Google Scholar
28 Ley, A, Jeffery, D, Ruiz, J, McLaren, S, Gillespie, C. Underdetection of comorbid drug use at acute psychiatric admission. Psychiatr Bull 2002; 26: 248–51.Google Scholar
29 Caton, CLM, Hasin, DS, Shrout, PE, Drake, RE, Dominguez, B, First, MB, et al. Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. Br J Psychiatry 2007; 190: 105–11.Google Scholar
30 Mathias, S, Lubman, DI, Hides, L. Substance-induced psychosis: a diagnostic conundrum. J Clin Psychiatry 2008; 69: 358–67.Google Scholar
31 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision (DSM-IV-TR). APA, 2000.Google Scholar
32 World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2007: Ch. 5, F00-F99. WHO, 2007 (http://apps.who.int/classification/apps/icd/icd10online).Google Scholar
33 Marshall, M, Lewis, S, Lockwood, A, Drake, R, Jones, P, Croudace, T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005; 62: 975–83.Google Scholar
34 Crebbin, K, Mitford, E, Paxton, R, Turkington, D. First episode drug-induced psychosis: a medium term follow up study reveals a high-risk group. Soc Psychiatry Psychiatr Epidemiol 2009; 44: 710–5.Google Scholar
35 Dawson, R, Green, AI, Drake, RE, Lavori, PW, McGlashan, TH, Schanzer, B. An adaptive treatment strategy paradigm for longitudinal treatment research using substance-induced psychosis as an example. Psychopharmacol Bull 2008; 41: 5167.Google Scholar
36 Drake, RE, Caton, CLM, Xie, H, Hsu, E, Gorroochurn, P, Samet, S, et al. A prospective 2-year study of emergency department patients with early-phase primary psychosis or substance-induced psychosis. Am J Psychiatry 2011; 31 Mar (doi: 10.1176/appi.ajp.2011.10071051).Google Scholar
37 Schanzer, MB, First, MB, Dominguez, B, Hasin, DS, Caton, CLM. Diagnosing psychotic disorders in the emergency department in the context of substance use. Psychiatr Serv 2006; 57: 1468–73.CrossRefGoogle ScholarPubMed
38 Hall, W, Degenhardt, L. What are the policy implications of the evidence on cannabis and psychosis? Can J Psychiatry 2006; 51: 566–74.Google Scholar
39 Miller, WR, Rollnick, S. Motivational Interviewing: Preparing People for Change. Guilford Press, 2002.Google Scholar
40 National Institute on Drug Abuse. A Cognitive Behavioral-Approach: Treating Cocaine Addiction. NIDA (http://archives.drugabuse.gov/txmanuals/cbt/cbt3.html).Google Scholar
41 Burns, T, Firn, M. Assertive Outreach in Mental Health: A Manual for Practitioners. Oxford University Press, 2002.Google Scholar
42 Tyrer, P, Weaver, T. Desperately seeking solutions: the search for appropriate treatment for comorbid substance misuse and psychosis. Psychiatr Bull 2004; 28: 12.Google Scholar
43 Johnson, S, Thornicroft, G, Afuwape, S, Leese, M, White, IR, Hughes, E, et al. Effects of training community staff in interventions for substance misuse in dual diagnosis patients with psychosis (COMO study). Cluster randomised trial. Br J Psychiatry 2007; 191: 451–2.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.